Ki-67多克隆抗体评价非小细胞肺癌的增殖活性及预后的研究  

The study of the polyclonal antibody Ki-67 estimating tumor proliferative activity and prognosis in non-small cell lung cancer

作　　者：王德华[1] 廖松林[1] 高子芬[1] 张惠信[2] 白逸秋[2] 许翔[2] 

机构地区：[1]北京医科大学病理学系,100083 [2]北京市安贞医院病理科

出　　处：《诊断病理学杂志》1997年第2期77-79,共3页Chinese Journal of Diagnostic Pathology

摘　　要：为进一步探讨Ki-67抗原评价非小细胞肺癌（NSCLC）的增殖活性和预后方面的价值，本文采用Ki-67多克隆抗体对85例有详细的临床、病理和随访资料的非小细胞肺癌进行了免疫组化研究。病人的平均年龄55．6±8．4岁；3年、5年总体生存率分别为66％和61％；中位随访时间为47个月；Ki-67平均标记率为30％±24％，此标记率明显高于其它研究者的研究结果；Ki-67标记率与病人的临床病理特征无关（P＞0．05）；Ki-67标记率＜3O％组病人的3年、5年生存率分别为80％、75％，≥30％组病人的3年、5年生存率分别为52％、49％，两组之间有显著性差别（X2=4．91，P=0．03）。以上结果提示：Ki-67多克隆抗体较单克隆抗体能更好地反映肿瘤的增殖活性，并可作为NSCLC的辅助预后指标。In order to further study the value of Ki-67 antigen estirnating tumor proliferative activity and prognosisin non-small cell lung cancer (NSCLC), 85 cases of NSCLC with detail clinical pathological and follow-up materials were studied by irnmunohistochemistry. The patients' mean age was 55. 6±8. 4 years. The median follow-upwas 47 months. The rate of overall 3-year survival was 66% and that of overall 5-year survival was 61 %. Themean Ki-67 labeling rate was 30%±24% obviously higher than that of other researches. Ki-67 labeling rate didnot correlate with the clinical and pathological characteristics of patients (P＞0. 05). 3 year and 5 year survivalrates of the patient groups with less than 30% Ki-67 labeling rate were respectively 80% and 75%, and that of thepatient groups with more than and equal to 30% Ki-67 labeling rate were 52 % and 49 % respectively. There wassignificant difference between the two groups (x2 = 4. 91, P = 0. 03). The results suggest that the polyclonal antibody Ki-67 estimating tumor proliferative activity is better than the monoclonal antibody and it could be an adjuvant prognostic indicator of NSCLC.

关 键 词：多克隆抗体 KI-67抗原 非小细胞肺癌 预后 

分 类 号：R734.207[医药卫生—肿瘤]